PM Q3 2025: Revenue & EPS Rise, Guidance Raised

On Oct. 21, 2025, Philip Morris (PM) reported a quarter marked by revenue and EPS growth and said it was raising full-year guidance. Management cited continued momentum in smoke-free products (SFPs) as a key growth engine. The company’s 2025 operating profile shows SFPs gaining scale: SFPs represented 22.8% of total 2025 shipment volume and the company recorded double-digit growth rates across HTU and oral SFP categories (HTU +11.0% YoY; oral SFP +18.5% YoY). E-vapor showed sharp percentage growth from a small base (e-vapor +100% YoY). Those dynamics — broader adoption of IQOS and the ZYN oral nicotine franchise — are consistent with management’s stated smoke-free transition and explain the outsized contribution of SFPs to the quarter’s results. Geographically, Europe remains a primary source of HTU and oral SFP growth while the Americas reflect ongoing IQOS and ZYN ramp-up in the U.S. following the company’s reinstated commercial rights. Marlboro remains a dominant cigarette brand in key markets, supporting overall cigarette pricing and margins even as shipment volumes gradually shift toward SFPs.

Full-year 2025 financials provided by the company frame the quarter: net revenues of $40,648 million, gross profit of $27,282 million, operating income of $14,892 million and net earnings of $11,848 million. Balance-sheet items of note include long-term debt of $45,134 million and a reported stockholders’ deficit of $(8,028) million. Investors should weigh the operational progress in SFP scale against a defined set of legal, regulatory and macro risks cited by the company. Legal exposures include multiple U.S. ZYN-related suits and large legacy tobacco claims (e.g., proposed Canadian litigation settlement considerations noted in prior disclosures). Regulatory reviews — from novel-product notifications to tax and classification disputes in jurisdictions such as Germany and ongoing FDA-related processes for MRTP determinations — remain discrete downside drivers. Currency volatility and elevated rates also present earnings sensitivity given the company’s global footprint and leverage. From a competitive and strategic standpoint, the company’s advantages are execution- and brand-driven rather than clearly structural. Marlboro and IQOS deliver pricing and product leverage, but patents and cost advantages face competitive pressure. For investors, the Q3 results and raised guidance reinforce progress on the smoke-free transition, while balance-sheet leverage and litigation/regulatory risk warrant careful monitoring.